INDICAID(R) COVID-19 Rapid Antigen Test certified by Cambodia's Ministry of Health for Disease Control
PR90181
HONG KONG and PHNOM PENH, Cambodia, June 22, 2021 /PRNewswire=KYODO JBN/ --
Cambodia's Ministry of Health has approved INDICAID(R) COVID-19 Rapid Antigen
Test for commercialisation as part of the country's efforts in controlling
recent spikes of COVID-19 cases in the region.
Rapid antigen tests like INDICAID(R) have been deployed by the Cambodian
Government for widescale screening measures in the capital city Phnom Penh and
neighbouring regions, taking advantage of the tests' short result time and
convenience to help the Government quickly identify COVID-19 patients and curb
the disease's spread. These tests have also enabled better containment
measures, effectively dividing the capital into red, orange, and yellow zones
depending on case numbers and transmission risks. INDICAID(R) is also available
in Phnom Penh for retail.
"We are confident that the accuracy, ease of use and affordability of our test
kits will position INDICAID(R) to play an important role of the Cambodian
Government's ongoing screening efforts in the region," says Ricky Chiu, Founder
and CEO of PHASE Scientific, the official manufacturer of the INDICAID(R) test
kits. "We welcome the Cambodian Government's decision and look forward to
bringing our rapid test kits to support its neighbouring countries as well."
According to Chiu, INDICAID(R) is adopted in multiple countries to combat
COVID-19. In Hong Kong, where PHASE Scientific is headquartered at, INDICAID(R)
has been endorsed by the Government as a designated product for hospital and
care home visitation, and is the top selling brand of its kind with over 2
million kits sold. It has also been widely adopted in hospitals, government and
private corporations, supermarkets, hotels and schools for regular screening
both locally and internationally.
The INDICAID(R) COVID-19 Rapid Antigen Test is a CE-marked lateral flow
immunoassay designed for the qualitative detection of SARS-CoV-2 antigens in
direct nasal swab samples. With reliable product quality and ease-of-use,
INDICAID(R) can provide fast results within 20 minutes with no special
equipment or facilities needed. The test kit's accuracy has been clinically
validated in the world's largest dual-track clinical trial, where INDICAID(R)
was tested against PCR in over 9,200 samples and was shown to demonstrate high
sensitivity and specificity.
INDICAID(R) is currently available in 33 countries, and in the process of
obtaining Emergency Use Authorization (EUA) from the US Food & Drug
Administration (FDA).
SOURCE PHASE Scientific
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。